IR vs NVAX · P/E 49, rev $3.90B vs P/E 2.5, rev $196.2M
Ingersoll Rand Inc (IR) versus Novavax Inc (NVAX) — a side-by-side from cached financials, not a winner call.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Novavax Inc (NVAX) is a biotechnology company listed on US.
Latest reported IR revenue for 2026-06-30 was $3.90B. Net income was $448.9M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Latest reported NVAX revenue for 2026-06-30 was $196.2M. Net income was -$62.9M. Revenue was up 40.6% from 2026-03-31 to 2026-06-30. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
IR currently screens at market cap $28.27B and trailing P/E 48.8. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
Not investment advice. Open the IR and NVAX stock pages for the full models.
Not investment advice.